Completed PHASE2 INTERVENTIONAL 3-arm NCT00749632

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence (FP1097-002)

An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence

Sponsor: FemmePharma Global Healthcare, Inc.

Conditions Urinary Incontinence, Urge

Interventions oxybutynin

Updated 7 times since 2017 Last updated: Oct 13, 2009 Started: Jul 31, 2007 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Urinary Incontinence, Urge, this trial is completed. The trial is conducted by FemmePharma Global Healthcare, Inc. and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

FemmePharma Global Healthcare, Inc.

Data source: FemmePharma Global Healthcare, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States
• Hackensack, United States